Clinical Trials
5
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
2 (40.0%)A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Phase 1
Recruiting
- Conditions
- Melanoma (Skin)Non Small Cell Lung CancerBreast Cancer
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Hummingbird Bioscience
- Target Recruit Count
- 180
- Registration Number
- NCT06956690
- Locations
- 🇦🇺
Research Site, Miranda, New South Wales, Australia
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)
Phase 2
Recruiting
- Conditions
- idiopathic pulmonary fibrosis
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Endeavor Biomedicines Inc.
- Target Recruit Count
- 140
- Registration Number
- 2024-511754-41-00
- Locations
- 🇬🇧
Research Site, Londonderry, United Kingdom
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05817240
- Locations
- 🇦🇺
Research Site, Adelaide, South Australia, Australia
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Phase 2
Active, not recruiting
- Conditions
- Solid Tumors With PTCH1 Loss-of-function Mutations
- Interventions
- Drug: ENV-101 (taladegib)
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05199584
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Endeavor Biomedicines, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04968574
- Locations
- 🇲🇽
Research Site, Puebla, Mexico
🇰🇷Research Site (Namdong District), Incheon, Korea, Republic of
🇰🇷Research Site (Bundang District), Seongnam, Korea, Republic of
News
No news found